Butyrylcholinesterase K variants increase the risk of coronary artery disease in the population of western Iran

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 2, 2008, Pages 123-129

  Vaisi Raygani, A ^a   Rahimi, Z ^a,b   Entezami, H ^a   Kharrazi, H ^a   Bahrhemand, F ^a   Tavilani, H ^a,c   Rezaei, M ^a   Kiani, A ^b   Nomanpour, B ^a   Pourmotabbed, T ^a,d  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Butyrylcholinesterase K variant; Coronary artery disease; Genetics; Polymorphism; Type 2 diabetes mellitus

Indexed keywords

BUTYRYLCHOLINESTERASE K; CHOLINESTERASE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

BASE SEQUENCE; BUTYRYLCHOLINESTERASE; CORONARY ARTERY DISEASE; DNA PRIMERS; GENOTYPE; HUMANS; IRAN; POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 41649092462     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701576180     Document Type: Article

References (39)

1. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974;23:105-11.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
3. Schmitz F, Mevissen V, Krantz C, Kimmel M, Erdmann J, Hoffmann R, et al. Robust association of the APOE _4 allele with premature myocardial infarction especially in patients without hypercholesterolaemia: the Aachen study. Eur J Clin Invest 2007;37:106.
4. Jaikaran ETAS, Clark A. Islet amyloid and Type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 2001;1537:179-203.
5. (-1562)T polymorphism in relation to ischaemic heart disease. Scand J Clin Lab Invest 2005;65:513-22.
6. Pildal J, Lajer M, Hansen SK, et al. Studies of variability in the islet amyloid polypeptide gene in relation to Type 2 diabetes. Diabet Med 2003;20:491-4.
7. Primo-Parmo SL, Bartels CF, Wiersema B, van der Spek AFL, Innis JW, La Du BN. Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene. Am J Hum Genet 1996;58:52-64.
8. Bartels CF, Jensen FS, Lockridge O, et al. DNA mutation associated with the human butyrylcholinesterase K variant and its linkage the atypical variant mutation and other polymorphic sites. Am J Hum Genet 1992;50:1086-103.
9. Yen T, Nightingale BN, Burns JC, Sullivan DR, Stewart PM. Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in an Australian population. Clin Chem 2003;49:1297-308.
10. Souza RL, Mikami LR, Maegawa RO, Chautard-Freire-Maia EA. Four new mutations in the BCHE gene of human butyrylcholinesterase in a Brazilian blood donor sample. Mol Genet Metab 2005;84:349-53.
11. Pepys MB, Hawkins PN, Booth DR, et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 1993;362:553-7.
12. Hashim Y, Shepherd D, Wiltshire S, Holman RR, Levy JC, Clark A, et al. Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects. Diabetologia 2001;44:2227-30.
13. Lepienski LM, Souza RL, Chautard-Freire-Maia EA, Alcantara VM, Rea RR. Variant K of butyrylcholinesterase and risk of early-onset type 1 diabetes mellitus in Euro-Brazilians. Diabetes Obes Metab 2006;8:709-11.
14. Johansen A, Nielsen EM, Andersen G, Hamid YH, Jensen DP, Glumer C, et al. Large-scale studies of the functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes and insulin secretion. Diabetologia 2004;47:1437-41.
15. Nassar BA, Rockwood K, Kirkland SA, Ransom TP, Darvesh S, Macpherson K, et al. Improved prediction of early-onset coronary artery disease using APOE epsilon4, BChE-K, PPARgamma2 Pro12 and ENOS T-786C in a polygenic model. Clin Biochem Clin Iochem 2006;39:109-14.
16. Nassar BA, Darvesh S, Bevin LD, Rockwood K, Kirkland SA, O'Neill BJ, et al. Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E epsilon 4 genes in early-onset coronary artery disease. Clin Biochem 2002;35:205-9.
17. Raygani AV, Zahrai M, Solt Anzadeh A, Doosti M, Javadi E, Pourmotabbed T. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease. Neurosci Lett 2004;371:142-6.
18. Judkins MP. Selective coronary arteriography. I. A percutaneous transfemoral technique. Radiology 1967;89:815-24.
19. WHO Study Group Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization;1999.
20. Johan SWM, Weitzner G, Rozen R. A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acids Res 1991;19:408.
21. Jenese FS, Nielsen LR, Schwartz M. Detection of the plasma cholinesterase K variant by PCR using amplification-created restriction site. Hum Heard 1996;46:26-31.
22. Arnaud J, Brun R, Liobera R, Constans J. Serum cholinesterase polymorphism in France: an epidemiological survey of the deficient alleles detected by an automated micro-method. Ann Hum Biol 1991;18:1-8.
23. Garry PJ. A manual and automated procedure for measuring serum cholinesterase activity and identifying enzyme variants. Differentiation by means of Tris and phosphate buffers. Clin Chem 1971;16:183-91.
24. Boutin D, Brodeur J. An automated method for simultaneous determination of serum pseudocholinesterase activity, dibucaine number and fluoride number. Clin Biochem 1990;23:423-31.
25. Vaisi-Raygani A, Rahimi Z, Kharazi H, Tavilani H, Aminian M, Poumotabbed T, et al. Determination of butyrylcholinesterase (BChE) phenotypes to predict the risk of prolonged apnea in persons receiving succinylcholine in the healthy population of western Iran. Clin Biochem 2007;40:629-33.
26. Alcantara VM, Chautard-Freire-Maia EA, Scartezini M, Cerci MS, Braun-Prado K, Picheth G. Butyrylcholinesterase activity and risk factors for coronary artery disease. Scand J Clin Lab Invest 2002;62:399-404.
27. Rustemeijer R, Schouten JA, Voerman HJ, Beyenen AC, Donker AJM, Heine RJ. Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus? Clin Sci 2001;101:29-35.
28. Humphries SE, Ridker PM, Talmud PJ. Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation. Arterioscler Thromb Vasc Biol 2004;24:628-36.
29. Gandelman G, Bodenheimer MM. Screening coronary arteriography in the primary prevention of coronary artery disease. Heart Dis 2003;5:335-44.
30. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphism in candidate genes. N Engl J Med 2002;347:1916-23.
31. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997;6:1933-6.
32. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. β-amyloid mediated vasoactivity, and vascular endothelial damage. Nature 1996;380:168-71.
33. Altamirano CV, Bartels CF, Lockridge O. The butyrylcholinesterase K-variant shows cellular protein turnover and quaternary interaction to the wild-type enzyme. J Neurochem 2000;74:869-77.
34. Lehmann DJ, Nagy Z, Litchfield S, Cortina Borja M, Smith DA. Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease. Hum Genet 2000;106:447-52.
35. Kutty KM, Rowden G, Cox AR. Interrelationship between serum β-lipoprotein and cholinesterase. Can J Biochem 1973;51:883-7.
36. Randell EW, Mathews MS, Zhang H, Seraj JS, Sun G. Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clin Biochem 2005;38:799-805.
37. Abbott CA, Mackness MI, Kumar S, Olukoga AO, Gordon C, Arrol S, et al. Relationship between butyrylcholinesterase activity, hypertriglyceridemia and insulin sensitivity in diabetes mellitus. Clin Sci 1993;85:77-81.
38. Sridhar GR, Nirmala G, Apparao A, Madhavi AS, Sreelatha S, Rani S, et al. Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach. Lipids Health Dis 2005;4:1-5.
39. Rao AA, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses 2007. In press.